This article was originally published in Drug Discovery Online. By Andrew Alexander, DVM, Ph.D., MBA, DABT, senior director of preclinical toxicology, Lovelace Biomedical For early-stage biotech companies, the instinct to build a comprehensive preclinical data package is understandable. Scientific credibility, regulatory readiness, and investor confidence are often tied to the depth of available data. In practice, however, this approach frequently leads ... Read More The post Designing Data For Funding: Preclinical Development Strategies For Startups appeared first on Lovelace Biomedical .